To mimic the clinical condition in patients, intratumor or systemic administration of PBMCs to mouse xenograft model will be required, which will disclose the precise mechanisms underlying the anti-tumor effect of perforin in tumor microenvironment. This evidence concerns the gene PRF1 and neoplasm.